WGS vs. PRVA, USPH, PNTG, INNV, TALK, DCGO, SHCR, PIII, EUDA, and ATPC
Should you be buying GeneDx stock or one of its competitors? The main competitors of GeneDx include Privia Health Group (PRVA), U.S. Physical Therapy (USPH), The Pennant Group (PNTG), InnovAge (INNV), Talkspace (TALK), DocGo (DCGO), Sharecare (SHCR), P3 Health Partners (PIII), EUDA Health (EUDA), and Agape ATP (ATPC). These companies are all part of the "health services" industry.
Privia Health Group (NASDAQ:PRVA) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation.
Privia Health Group has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, GeneDx has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500.
Privia Health Group currently has a consensus price target of $24.92, indicating a potential upside of 43.48%. GeneDx has a consensus price target of $18.00, indicating a potential downside of 8.21%. Given GeneDx's stronger consensus rating and higher probable upside, equities research analysts plainly believe Privia Health Group is more favorable than GeneDx.
Privia Health Group has a net margin of 1.11% compared to Privia Health Group's net margin of -60.86%. GeneDx's return on equity of 3.13% beat Privia Health Group's return on equity.
94.5% of Privia Health Group shares are owned by institutional investors. Comparatively, 61.7% of GeneDx shares are owned by institutional investors. 14.2% of Privia Health Group shares are owned by insiders. Comparatively, 28.1% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Privia Health Group received 54 more outperform votes than GeneDx when rated by MarketBeat users. Likewise, 73.08% of users gave Privia Health Group an outperform vote while only 42.86% of users gave GeneDx an outperform vote.
In the previous week, Privia Health Group had 6 more articles in the media than GeneDx. MarketBeat recorded 17 mentions for Privia Health Group and 11 mentions for GeneDx. Privia Health Group's average media sentiment score of 1.20 beat GeneDx's score of 0.95 indicating that GeneDx is being referred to more favorably in the news media.
Privia Health Group has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.
Summary
Privia Health Group beats GeneDx on 15 of the 19 factors compared between the two stocks.
Get GeneDx News Delivered to You Automatically
Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
